Global Injectable Drug Delivery Market, By Type (Devices (Conventional Injection Devices, Self Injection Devices), Formulations (Conventional Drug Delivery, Noble Drug Delivery, Long Acting Injection Formulations), By Applications (Autoimmune Diseases, Hormonal Disorders, Orphan Diseases, Oncology, Others), By Usage Pattern (Curative Care, Immunizations, Other Usage Patterns), By Mode of Administration (Skin, Circulatory, Organs, Central Nervous System), By End User (Hospitals, Clinics, Home Care Settings, Research Laboratories, Pharma & Biotech Companies), By Geography (North America, Europe, Asia-Pacific, South America, Rest of the World) – Trends and Forecast to 2022
Global Injectable drug delivery market is expected to reach USD 797.2 billion by 2022, from USD 343.2 billion in 2015 growing at a CAGR of 12.7% during the forecast period of 2016 to 2022.
For Sample Report: http://databridgemarketresearch.com/reports/global-injectable-drug-delivery-market/
The global injectable drug delivery market is segmented based on product type, application, usage pattern, mode of administration, end-user and geography.
Based on product type the market is segmented into Devices and Formulations. Devices include conventional injection devices and self-injection devices. The Self Injection devices are further segmented into needle free injector devices, wearable injector devices, pen injector devices and autoinjector devices. Formulations are segmented into conventional drug delivery, novel drug delivery, and long-acting injection formulations. Conventional drug delivery formulations market is further segmented into solutions, reconstituted formulations, suspensions and emulsions. Novel drug delivery formulations market is further segmented based on product type into colloidal dispersions and microparticles. Colloidal dispersions include products such as niosomes, liposomes, polymeric mixed micelles and nanoparticles.
On the basis of applications the global Injectable drug delivery market is segmented into hormonal disorders, oncology, autoimmune diseases, orphan diseases, and others.
To read more about the scope and findings of this report visit: http://databridgemarketresearch.com/injectable-drug-delivery-market-reach-usd-797-2/
On the basis of usage pattern the global injectable drug delivery market is segmented into curative care, immunization and, others.
Based on mode of administration the market is segmented into skin, circulatory, organs and central nervous system.
On the basis of end user the global Injectable drug delivery market is segmented into hospitals, clinics, home care settings, research laboratories and, pharma & biotech companies.
Based on geography, the market report covers data North America, Europe, Asia-Pacific, South America and rest of the world. The reports of this market further segmented into countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, and South Africa.
Major players operating in the global injectable drug delivery market are Baxter International, Inc., Becton Dickinson and Company, Gerresheimer AG, Pfizer, Inc., Schott AG, Alkermes Plc., Eli Lilly and Company, Sandoz, Terumo Corporation, Teva Pharmaceuticals Industries Ltd.
To Browse Full Report and Pricing: http://databridgemarketresearch.com/reports/global-injectable-drug-delivery-market/
Table of Content:
1 INTRODUCTION
1.1. OVERVIEW OF THE INJECTABLE DRUG DELIVERY MARKET
1.2. MARKET SEGMENTATION & COVERAGE
1.2.1. CURRENCY AND PRICING
1.2.2. LIMITATION
1.2.3. STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1. KEY TAKEAWAYS
2.2. ARRIVING AT THE INJECTABLE DRUG DELIVERY MARKET SIZE
2.2.1. MARKET CRACKDOWN APPROACH
2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS
2.2.3. DATA TRIANGULATION
2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES
2.2.5. KEY DATA POINTS FROM SECONDARY SOURCES
2.2.6. PORTER’S FIVE FORCES MATRIX
2.3. GLOBAL INJECTABLE DRUG DELIVERY MARKET: RESEARCH SNAPSHOT
2.4. ASSUMPTIONS
3 MARKET LANDSCAPE SUMMARY
4 PREMIUM INSIGHTS
4.1. OVERVIEW
4.2. INJECTABLE DRUG DELIVERY MARKET: KEY PRIMARY INSIGHTS
4.3. MARKET OVERVIEW
4.3.1. DRIVERS
4.3.1.1. RISING PREVALENCE OF CHRONIC DISEASES
4.3.1.2. INCRESING DEMAND OF SELF INJECTION DEVICES
4.3.1.3. GROWTH OF BILOGICS AND BIOSIMILARS MARKET
4.3.1.4. TECHNOLOGICAL ADVANCEMENTS IN DRUG DELIVERY MARKET
4.3.2. RESTRAINTS
4.3.3. OPPURTUNITIES
4.3.3.1. INCRESING DEMAND FOR GENERIC INJECTABLES
4.3.4. THREATS
4.3.4.1. PRODUCT RECALLS
4.3.4.2. REGULATORY HURDLES
4.3.4.3. STABILITY OF PRODUCTS
4.3.4.4. STERILITY OF INJECTIONS
4.3.4.5. GROWING DEMAND OF OTHER DRUG DELIVERY TECHNOLOGIES
4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES
5 INJECTABLE DRUG DELIVERY MARKET, BY TYPE
5.1. OVERVIEW
5.2. INJECTABLE DRUG DELIVERY DEVICES
5.3. INJECTABLE DRUG DELIVERY FORMULATIONS
6 INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE
6.1. OVERVIEW
6.2. CONVENTIONAL INJECTION DEVICES
6.2.1. BY MATERIAL
6.2.1.1. GLASS
6.2.1.2. PLASTIC
6.2.2. BY PRODUCT
6.2.2.1. EMPTY SYRINGES
6.2.2.2. PREFILLED SYRINGES
6.2.3. BY USABLITY
6.2.3.1. REUSABLE SYRINGES
6.2.3.2. DISPOSABLE SYRINGES
6.3. SELF INJECTION DEVICES
6.3.1. NEEDLE FREE INJECTORS
6.3.1.1. BY PRODUCT
6.3.1.1.1. EMPTY NEEDLE FREE INJECTORS
6.3.1.1.2. PREFILLED NEEDLE FREE INJECTORS
6.3.1.2. BY TECHNOLOGY
6.3.1.2.1. JET BASED NEEDLE FREE INJECTORS
6.3.1.2.2. SPRING BASED NEEDLE FREE INJECTORS
6.3.1.2.3. LASER POWERED NEEDLE FREE INJECTORS
6.3.1.2.4. VIBRATION BASED NEEDLE FREE INJECTORS
6.3.1.3. BY USABILITY
6.3.1.3.1. REUSABLE NEEDLE FREE INJECTORS
6.3.1.3.2. DISPOSABLE NEEDLE FREE INJECTORS
6.3.2. AUTOINJECTORS
6.3.2.1. BY PRODUCT
6.3.2.1.1. EMPTY AUTOINJECTORS
6.3.2.1.2. PREFILLED AUTOINJECTORS
6.3.2.2. BY TECHNOLOGY
6.3.2.2.1. AUTOMATED AUTOINJECTORS
6.3.2.2.2. MANUAL AUTOINJECTORS
6.3.2.3. BY DESIGN
6.3.2.3.1. STANDARDIZED AUTOINJECTORS
6.3.2.3.2. CUSTOMIZED AUTOINJECTORS
6.3.2.4. BY USABILITY
6.3.2.4.1. REUSABLE AUTOINJECTORS
6.3.2.4.2. DISPOSABLE AUTOINJECTORS
6.3.3. PEN INJECTORS
6.3.3.1. BY PRODUCT
6.3.3.1.1. SINGLE CHAMBERED PEN INJECTORS
6.3.3.1.2. DUAL CHAMBERED PEN INJECTORS
6.3.3.2. BY DESIGN
6.3.3.2.1. STANDARDIZED PEN INJECTORS
6.3.3.2.2. CUSTOMIZED PEN INJECTORS
6.3.3.3. BY USABILITY
6.3.2.3.1. REUSABLE PEN INJECTORS
6.3.2.3.2. DISPOSABLE PEN INJECTORS
6.3.4. WEARABLE INJECTORS
6.3.5. OTHER INJECTABLE DEVICES
7 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE
7.1. OVERVIEW
7.2. CONVENTIONAL DRUG DELIVERY FORMULATIONS
7.2.1. SOLUTIONS
7.2.2. RECONSTITUTED/LYOPHILIZED FORMULATIONS
7.2.3. SUSPENSIONS
7.2.4. EMULSIONS
7.3. NOVEL DRUG DELIVERY FORMULATIONS
7.3.1. COLLOIDAL DISPERSIONS
7.3.1.1. LIPOSOMES
7.3.1.2. NIOSOMES
7.3.1.3. POLYMERIC MIXED MICELLES
7.3.1.4. NANOPARICLES
7.3.1.4.1. NANOSUSPENSIONS
7.3.1.4.2. NANOEMULSIONS/MICROEMULSIONS
7.3.1.4.3. SOLID LIPID NANOPARTICLES
7.3.2. MICROPARTICLES
7.3.2.1. MICROSPHERES
7.3.2.2. MICROCAPSULES
7.3.3. LONG ACTING INJECTION FORMULATIONS
8 INJECTABLE DRUG DELIVERY MARKET, BY APPLICATIONS
8.1. OVERVIEW
8.2. AUTOIMMUNE DISEASES
8.2.1. RHEUMATOID ARTHRITIS
8.2.2. MULTIPLE SCLEROSIS
8.2.3. CHRON’S DISEASE
8.2.4. PSORIASIS
8.2.5. OTHER AUTOIMMUNE DISEASES
8.3. HORMONAL DISORDERS
8.3.1. DIABETES
8.3.2. ANEMIA
8.3.3. REPRODUCTIVE HEALTH DISEASE
8.3.4. ANTITHROMBOTIC/THROMBOLYTIC THERAPY
8.3.5. OSTEOPOROSIS
8.3.6. GROWTH HORMONE DEFICIENCY (GHD)
8.4. ORPHAN DISEASES
8.5. ONCOLOGY
8.6. OTHERS
8.6.1. PAIN MANAGEMENT
8.6.2. ALERGY TREATMENT
8.6.3. AESTHETIC TREATMENTS
8.6.4. HEPATITIS C
8.6.5. HEMOPHILIA
9 INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN
9.1. OVERVIEW
9.2. CURATIVE CARE
9.3. IMMUNIZATIONS
9.4. OTHER USAGE PATTERNS (BLOOD TRANSFUSION, BLOOD PRODUCTS, AND CONTRACEPTIVES)
10 INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION
10.1. OVERVIEW
10.2. SKIN
10.3. CIRCULATORY/MUSKOSKELETAL
10.4. ORGANS
10.5. CENTRAL NERVOUS SYSTEM
11 INJECTABLE DRUG DELIVERY MARKET, BY END USER
11.1. OVERVIEW
11.2. HOSPITALS AND CLINICS
11.3. HOME HEALTHCARE SETTINGS
11.4. RESEARCH LABORATORIES
11.5. PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES
11.6. OTHER END USERS
12 INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY
12.1. COUNTRYWISE SLEEP APNEA DEVICES MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
12.1.1. NORTH AMERICA
12.1.1.1. U.S.
12.1.1.2. CANADA
12.1.1.3. MEXICO
12.1.2. EUROPE
12.1.2.1. GERMANY
12.1.2.2. FRANCE
12.1.2.3. U.K.
12.1.2.4. ITALY
12.1.2.5. SPAIN
12.1.2.6. RUSSIA
12.1.2.7. TURKEY
12.1.2.8. BELGIUM
12.1.2.9. NETHERLANDS
12.1.2.7. SWITZERLAND
12.1.2.8. REST OF EUROPE
12.1.3. ASIA-PACIFIC (APAC)
12.1.3.1. JAPAN
12.1.3.2. CHINA
12.1.3.3. SOUTH KOREA
12.1.3.4. INDIA
12.1.3.5. AUSTRALIA
12.1.3.6. SINGAPORE
12.1.3.7. THAILAND
12.1.3.8. MALAYSIA
12.1.3.9. INDONESIA
12.1.3.10. PHILIPPINES
12.1.3.11. REST OF APAC
12.1.4. LATIN AMERICA
12.1.4.1. BRAZIL
12.1.4.2. REST OF LATIN AMERICA
12.1.5. MIDDLE EAST AND AFRICA
12.1.5.1. SOUTH AFRICA
12.1.5.2. REST OF MIDDLE EAST AND AFRICA
12.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
13 INJECTABLE DRUG DELIVERY MARKET: COMPETITIVE LANDSCAPE
13.1. GLOBAL INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.2. U.S. INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.3. EUROPE INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.4. APAC INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.5. SOUTH AMERICA INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.6. MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.7. MERGERS & ACQUISITIONS
13.8. NEW PRODUCT DEVELOPMENT & APPROVALS
13.9. EXPANSIONS
13.10. REGULATORY CHANGES
13.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
14 INJECTABLE DRUG DELIVERY MARKET, COMPANY PROFILES
14.1 BAXTER INTERNATIONAL, INC.
14.1.1 OVERVIEW
14.1.2 SWOT ANALYSIS
14.1.3 PRODUCT PORTFOLIO
14.1.4 REVENUE ANALYSIS
14.1.5 ANALYSTS VIEW
14.2 BECTON, DICKINSON AND COMPANY
14.2.1 OVERVIEW
14.2.2 SWOT ANALYSIS
14.2.3 PRODUCT PORTFOLIO
14.2.4 REVENUE ANALYSIS
14.2.5 ANALYSTS VIEW
14.3 GERRESHEIMER, AG
14.3.1 OVERVIEW
14.3.2 SWOT ANALYSIS
14.3.3 PRODUCT PORTFOLIO
14.3.4 REVENUE ANALYSIS
14.3.5 ANALYST VIEW
14.4 PFIZER, INC.
14.4.1 OVERVIEW
14.4.2 SWOT ANALYSIS
14.4.3 PRODUCT PORTFOLIO
14.4.4 REVENUE ANALYSIS
14.4.5 ANALYSTS VIEW
14.5 SCHOTT AG
14.5.1 OVERVIEW
14.5.2 SWOT ANALYSIS
14.5.3 PRODUCT PORTFOLIO
14.5.4 REVENUE ANALYSIS
14.5.5 ANALYSTS VIEW
14.6 ALKERMES PLC
14.6.1 OVERVIEW
14.6.2 SWOT ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 REVENUE ANALYSIS
14.6.5 ANALYSTS VIEW
14.7 ELI LILLY AND COMPANY
14.7.1 OVERVIEW
14.7.2 SWOT ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 REVENUE ANALYSIS
14.7.5 ANALYSTS VIEW
14.8 SANDOZ
14.8.1 OVERVIEW
14.8.2 SWOT ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 REVENUE ANALYSIS
14.8.5 ANALYSTS VIEW
14.9 TERUMO CORPORATION
14.9.1 OVERVIEW
14.9.2 SWOT ANALYSIS
14.9.3 PRODUCT PORTFOLIO
14.9.4 REVENUE ANALYSIS
14.9.5 ANALYSTS VIEW
14.10 TEVA PHARMACEUTICAL INDUSTRIES LTD.
14.10.1 OVERVIEW
14.10.2 SWOT ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 REVENUE ANALYSIS
14.10.5 ANALYSTS VIEW
15 APPENDIX
15.1 RELATED REPORTS
15.2 CUSTOMIZABLE OPTIONS
15.3 SOURCE SHEET
15.4 BIBLIOGRAPHY
16 ABOUT DATA BRIDGE MARKET RESEARCH
About Data Bridge Market Research:
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are one of the largest market research firms in terms of number of reports produced, also we are proud to be the makers of the lengthiest reports in the industry owing to our in depth segmentation and large geographical coverage. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Reports:
Global Drug Delivery Devices Market – Trends and Forecast to 2022
By Product Type (Oral (Solid, Liquid,Semi-Solid), Injectable (Devices (Conventional, Self-Injectable), Formulations), Topical (Transdermal Devices (Patches, Gels), Formulations), Pulmonary (MDI, DPI, Nebulizers), Nasal, Ocular, Implantable, Transmucosal), By End-User (Hospitals, Clinics, Home Healthcare, Community Healthcare, Others), By Distribution Channel (Hospital Pharmacy, Pharmacy Stores, Direct Tenders, Online Pharmacy), By Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa, Rest of the World) – Trends and Forecast to 2022
Global Cord Stem Cell Banking Market – Trends and Forecast to 2022
By Storage Type (Private Banking, Public Banking), By Product Type (Cord Blood, Cord Blood & Cord Tissue), By Service Type (Collection & Transportation, Processing, Analysis, Storage), By Source (Umbilical Cord Blood, Bone Marrow, Peripheral Blood Stem, Menstrual Blood), By Indication (Cerebral Palsy, Thalassemia, Leukemia, Diabetes, Autism), By Geography (North America, Europe, Asia-Pacific, South America, Rest of the World) – Trends and Forecast to 2022
Media Contact
Company Name: Data Bridge Market Research Private Limited
Contact Person: Shubham Dwivedi
Email: Sales@databridgemarketresearch.com
Phone: +1-888-387-2818
Address:Mega Center, Magarpatta City
City: Pune
State: Maharashtra
Country: India
Website: http://databridgemarketresearch.com/reports/global-injectable-drug-delivery-market/